Literature DB >> 20050980

Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics.

Elodie Kara1, Hong Lin, Philip G Strange.   

Abstract

There is much evidence to suggest that G protein coupled receptors exist as oligomers but the relevance to their function is unclear. We have, therefore, examined the binding of the radiolabelled agonist [(3)H]NPA to membranes of CHO cells expressing the D(2) dopamine receptor in dissociation rate experiments. When [(3)H]NPA dissociation was started by dilution, the dissociation rate in the absence of sodium ions was unaffected by addition of the antagonist/inverse agonist (+)-butaclamol, but was accelerated by addition of agonists e.g. dopamine, suggesting that the receptor was not behaving as a monomer with a single binding site. The very low efficacy partial agonist, aripiprazole provided an intermediate level of acceleration of dissociation. [(3)H]NPA dissociation experiments started by addition of ligands without dilution gave a similar pattern. [(3)H]NPA dissociation could also be accelerated by GTP. Dissociation of [(3)H]NPA in the presence of GTP and dopamine provided a greater acceleration than for either modulator alone, suggesting synergistic effects related to receptor/G protein interaction. When [(3)H]NPA dissociation experiments were performed in the presence of sodium ions, dissociation was faster than in their absence but the rate still depended on the ligand present in the assay. Overall the data cannot be explained by a ternary complex model and are consistent with an oligomeric receptor in which binding of [(3)H]NPA, as an example of an agonist ligand, can be modulated co-operatively by ligands binding elsewhere in the oligomer. Interactions with G proteins also occurs providing further modulation of [(3)H]NPA binding. Both agonists and G proteins are proposed to modulate the oligomer by switching high affinity agonist binding sites to low affinity sites.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20050980     DOI: 10.1111/j.1471-4159.2009.06554.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

1.  Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.

Authors:  N Kabli; N Martin; T Fan; T Nguyen; A Hasbi; G Balboni; B F O'Dowd; S R George
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  G protein-coupled receptors: walking hand-in-hand, talking hand-in-hand?

Authors:  Henry F Vischer; Anne O Watts; Saskia Nijmeijer; Rob Leurs
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 4.  Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction?

Authors:  Mette Skinbjerg; David R Sibley; Jonathan A Javitch; Anissa Abi-Dargham
Journal:  Biochem Pharmacol       Date:  2011-09-16       Impact factor: 5.858

5.  Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.

Authors:  Mark Slifstein; Raymond F Suckow; Jonathan A Javitch; Thomas Cooper; Jeffrey Lieberman; Anissa Abi-Dargham
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-23       Impact factor: 6.200

6.  A kinetic view of GPCR allostery and biased agonism.

Authors:  J Robert Lane; Lauren T May; Robert G Parton; Patrick M Sexton; Arthur Christopoulos
Journal:  Nat Chem Biol       Date:  2017-08-18       Impact factor: 15.040

7.  Reinterpreting anomalous competitive binding experiments within G protein-coupled receptor homodimers using a dimer receptor model.

Authors:  Verònica Casadó-Anguera; Estefanía Moreno; Josefa Mallol; Sergi Ferré; Enric I Canela; Antoni Cortés; Vicent Casadó
Journal:  Pharmacol Res       Date:  2018-11-22       Impact factor: 7.658

Review 8.  Dopamine receptor homooligomers and heterooligomers in schizophrenia.

Authors:  Melissa L Perreault; Brian F O'Dowd; Susan R George
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

9.  Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.

Authors:  Elodie Kara; Hong Lin; Kjell Svensson; Anette M Johansson; Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

10.  The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.

Authors:  Nelleke Tolboom; Henk W Berendse; Josee E Leysen; Maqsood Yaqub; Bart N M van Berckel; Robert C Schuit; Mirthe M Ponsen; Esther Bakker; Nikie J Hoetjes; Albert D Windhorst; Maria L Carlsson; Adriaan A Lammertsma; Arvid Carlsson
Journal:  Neuropsychopharmacology       Date:  2014-08-05       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.